2025
The role of long non-coding ribonucleic acid HOXA11-AS in endometriosis therapy
Mamillapalli R, Gawde N, Fay M, Atwani R, Moridi I, Taylor H. The role of long non-coding ribonucleic acid HOXA11-AS in endometriosis therapy. Reproductive Biology And Endocrinology 2025, 23: 83. PMID: 40457415, PMCID: PMC12128536, DOI: 10.1186/s12958-025-01420-0.Peer-Reviewed Original ResearchConceptsHOXA11-ASHOXA11-AS expressionEutopic endometriumLong non-coding RNAsEctopic endometriotic lesionsEndometriotic cell linesInvasion of endometriosisEndometrial stromal cellsReal-time polymerase chain reactionNon-coding RNAsEndometriotic lesionsEndometriosis therapyEndometriosis patientsNormal endometriumProgestin responsivenessEndometrial developmentTreatment responsePolymerase chain reactionQuantitative real-time polymerase chain reactionEndometriosisEndometriosis treatmentMethodsTissue samplesStromal cellsPotential target genesEndometrium
2020
Emerging therapies for endometriosis
Taylor HS. Emerging therapies for endometriosis. Fertility And Sterility 2020, 115: 317-318. PMID: 33386111, DOI: 10.1016/j.fertnstert.2020.11.005.Peer-Reviewed Original ResearchEstrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Pluchino N, Mamillapalli R, Wenger JM, Ramyead L, Drakopoulos P, Tille JC, Taylor HS. Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. Fertility And Sterility 2020, 113: 1224-1231.e1. PMID: 32416979, DOI: 10.1016/j.fertnstert.2020.01.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersConstipationCross-Sectional StudiesDysmenorrheaDyspareuniaEndometriosisEstrogen Receptor alphaFemaleHumansImmunohistochemistryMiddle AgedPain MeasurementPredictive Value of TestsProgestinsRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexTissue Array AnalysisTreatment OutcomeYoung AdultConceptsER-α expressionNumerical rating scaleProgesterone receptorAndrogen receptorDeep dyspareuniaDeep endometriosisImmunoreactive scoreProgestin therapyReceptor expressionTissue microarrayExpression of PRMultivariate logistic regression analysisER-α levelsSteroid receptor expressionTime of surgerySeverity of dysmenorrheaSeverity of symptomsLogistic regression analysisNonmenstrual painPain recurrencePain symptomsSevere dysmenorrheaPain persistencePain severityProgestin treatment
2019
Response to Letter to the Editor: “Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis”
Flores VA, Vanhie A, Dang T, Taylor HS. Response to Letter to the Editor: “Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis”. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 2149-2149. PMID: 30657936, PMCID: PMC7296127, DOI: 10.1210/jc.2018-02712.Peer-Reviewed Original Research
2018
Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis
Flores VA, Vanhie A, Dang T, Taylor HS. Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 4561-4568. PMID: 30357380, PMCID: PMC6226602, DOI: 10.1210/jc.2018-01227.Peer-Reviewed Original ResearchConceptsProgestin-based therapyPR statusReceptor statusEndometriotic lesionsPredictive valueEndometriosis-associated painProgesterone receptor levelsRetrospective cohort studyFirst-line treatmentProgesterone receptor statusNegative predictive valuePositive predictive valueElectronic medical recordsRabbit polyclonal IgGPrecision-based approachesProgestin therapyHormonal therapyEndometriosis treatmentCohort studyPredictive markerMedical recordsReceptor levelsH-scoreAcademic centersEndometriosis
2017
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesteroneSafety and benefit considerations for menopausal hormone therapy
Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS. Safety and benefit considerations for menopausal hormone therapy. Expert Opinion On Drug Safety 2017, 16: 941-954. PMID: 28664754, DOI: 10.1080/14740338.2017.1343298.Peer-Reviewed Original ResearchConceptsSafety of HTConjugated equine estrogensHormone therapyEquine estrogensHealth initiativesDifferent estrogensEstrogen-progestogen therapyMenopausal hormone therapyUnexpected safety concernsWomen's Health InitiativeRoute of administrationHT initiationEffect of ageSafety profileDifferent progestogensCardiovascular diseaseObservational studySynthetic progestinsAdministration routeEstrogenTherapyClinical useSafety evidenceRegimensFurther studiesLongitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo
Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo. Menopause The Journal Of The North American Menopause Society 2017, 24: 238-246. PMID: 27779568, PMCID: PMC5323337, DOI: 10.1097/gme.0000000000000756.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAutonomic Nervous System DiseasesDrug Therapy, CombinationEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHot FlashesHumansIrritable MoodLongitudinal StudiesMiddle AgedPostmenopauseProgesteroneProgestinsSleep Initiation and Maintenance DisordersTreatment OutcomeVasomotor SystemConceptsOral conjugated estrogensActive treatment armsBody mass indexTreatment armsRace/ethnicityMonths postrandomizationNight sweatsPostmenopausal womenHot flashesMass indexMenopausal symptomsConjugated estrogensEarly postmenopausal womenMenopausal hormone therapyFinal menstrual periodProportion of womenHormone regimensTransdermal estradiolTransdermal estrogenHormone therapyVasomotor symptomsSymptom reliefTreat analysisActive treatmentConventional doses
2014
Current and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy for Menopausal Women
Santen RJ, Kagan R, Altomare CJ, Komm B, Mirkin S, Taylor HS. Current and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy for Menopausal Women. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 733-747. PMID: 24423357, DOI: 10.1210/jc.2013-3680.Peer-Reviewed Original ResearchConceptsTissue selective estrogen complexSelective ER modulatorsPostmenopausal womenEstrogen deficiencyMenopausal womenAvailable estrogen receptorRelevant English-language articlesHysterectomized postmenopausal womenLarge observational studiesReceptor-based therapiesEnglish-language articlesPossible adverse effectsOptimal therapeutic profileProgestogen useSystemic estrogenHormonal therapyHormone therapyTherapeutic guidelinesMenopausal symptomsEstrogen complexObservational studyDifferent therapiesEstrogen receptorER agonismIndividualized approach
2011
Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes
Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes. The American Journal Of Medicine 2011, 124: 199-205. PMID: 21396500, PMCID: PMC3107840, DOI: 10.1016/j.amjmed.2010.09.021.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCardiovascular SystemCoronary DiseaseDrug Administration ScheduleEstrogen Replacement TherapyEstrogensFemaleHumansMiddle AgedPostmenopausePrecision MedicineProgestinsRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsThromboembolismTime FactorsWomen's HealthConceptsMenopausal hormone treatmentCoronary heart disease riskHeart disease riskHormone treatmentExcess coronary heart disease riskWomen's Health Initiative hormone trialsDisease riskBeneficial effectsEstrogen-alone trialCoronary heart diseaseYears of treatmentNet harmTreatment-related risksRoute of administrationCurrent FoodShort durationDrug Administration recommendationsDisease incidence ratesWHI dataWHI estrogenWHI findingsCardiovascular outcomesProgestin trialMenopausal symptomsRisk ratio
1997
Alternative Medical Treatment for Endometriosis
Taylor H, Guarnaccia M, Olive D. Alternative Medical Treatment for Endometriosis. Seminars In Reproductive Medicine 1997, 15: 285-290. PMID: 9383837, DOI: 10.1055/s-2008-1068758.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply